Sunday, 11 October 2026
Ultrasound fault may disrupt scanning, Diagnosis-independent neurodevelopmental, GLP-1 eye damage lawsuits
- 01
Philips Lumify fault may delay or prevent ultrasound scanning
A software app or transducer connection problem in the Philips Lumify diagnostic ultrasound system can cause loss of or delays in scanning functionality. The fault may prevent scanning or delay it when the system is in use. FDA MedWatch issued an early alert about the device issue. The source gives no further details about affected units, corrective action or reported patient effects.
via FDA MedWatch
- 02
Review urges diagnosis-independent ADHD and autism support in England
Following earlier reports of assessment backlogs, a government-backed review has called for England to move away from an NHS support system tied to ADHD and autism diagnoses. The Fonagy review examined rising demand for mental health, ADHD and autism services and the factors driving it. It found that more than 254,000 people were waiting for an autism assessment in December 2025, while 560,000 were waiting for an ADHD assessment. NHS data estimates suggested autism had increased more than 20-fold among children aged 6–11 and more than 40-fold among those aged 12–17, with the review warning that continuing the current approach was unsustainable.
via BMJ
- 03
Drugmakers face lawsuits alleging eye damage from GLP-1 medicines
Dozens of people alleging eye damage from GLP-1 medicines are suing manufacturers Novo Nordisk and Eli Lilly. The claims involve semaglutide, sold as Ozempic, Wegovy and Rybelsus, and tirzepatide, sold as Mounjaro and Zepbound. These medicines are widely used to treat type 2 diabetes and promote weight loss. The lawsuits centre on non-arteritic anterior ischaemic optic neuropathy, the most common acute optic neuropathy in people aged over 50.
via BMJ
- 04
FDA documents show uneven Rasonque responses across KRAS mutations
FDA review documents showed uneven tumour responses to Rasonque among patients with pancreatic cancer, depending on their KRAS mutation. Responses were markedly better than chemotherapy in trial participants with G12V, more modest in those with G12D and worse in those with G12R. The finding is notable because G12D represents the largest share of pancreatic cancer patients, while the drug’s August approval followed data showing it nearly doubled survival compared with chemotherapy in patients whose disease had progressed on chemotherapy. Revolution Medicines shares fell 6%, although several analysts described the sell-off as excessive.
via BioPharma Dive
- 05
Go Gentle funds research into VAD for advanced dementia
Go Gentle has committed startup funding to research VAD practitioners’ attitudes and insights into expanding access for people with advanced dementia who lack decision-making capacity at the time of death. Australian law currently requires patients to retain full decision-making capacity throughout the process and provide verbal or written consent before lethal drugs are administered. Founder Andrew Denton described the issue as ethically, medically, legally and politically complex, and said any proposed framework would require substantial input from experienced VAD practitioners. The Netherlands and Canada allow access through informed consent in advance care directives, although uptake has been marginal; seven of the Netherlands’ 10,340 VAD deaths in 2025 involved advanced dementia. Go Gentle said a subsequent project would examine institutional obstruction, after its report card found only seven of 70 large aged-care providers offered residents comprehensive VAD information and access.
- 06
One Nation doctor proposal overlooks specialist training bottleneck
Limiting doctor migration and broadening medical school entry would likely worsen rather than solve Australia’s workforce problems, according to commentary in The Medical Republic. Victorian One Nation candidate Colleen Harker argued that more Australian students should enter medicine before Australia imports additional doctors. The commentary said internationally trained doctors comprise more than one-third of the medical workforce, while insufficient non-GP specialist training positions are expected to leave an oversupply of about 8000 prevocational doctors by 2033, up from 1391 currently. It cited a Grattan Institute paper that attributed the training bottleneck to specialist college priorities and public hospitals’ immediate service needs, and recommended making migration easier. The commentary argued that training capacity and alignment with community workforce needs, rather than internationally trained doctors, sit at the centre of the shortage.
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.